Vadastuximab

Vadastuximab (also known as SGN-CD33A) is a monoclonal antibody designed for the treatment of acute myeloid leukemia (AML). It is developed by Seattle Genetics and is currently in the clinical trial phase.

Mechanism of Action

Vadastuximab targets the CD33 antigen, a protein abundantly expressed on the surface of AML cells. The antibody is conjugated with a potent, synthetic DNA cross-linking agent, a pyrrolobenzodiazepine (PBD) dimer, which is designed to be released inside the targeted cells upon internalization, causing cell death.

Clinical Trials

Vadastuximab has been evaluated in several clinical trials for the treatment of AML. The Phase 1 trial demonstrated a favorable safety profile and anti-leukemic activity. However, the Phase 3 CASCADE trial was halted in 2017 due to a higher rate of deaths observed in the vadastuximab arm compared to the control arm.

Future Development

Despite the setback in the CASCADE trial, Seattle Genetics continues to evaluate the potential of vadastuximab in other clinical settings and in combination with other therapies.

See Also

• Monoclonal antibody
• Acute myeloid leukemia
• Clinical trial
• CD33 antigen

References

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian